Legend Biotech Corporation
(NASDAQ: LEGN)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $45.91 | Change: +1.17 | %Change: +2.62% | Volume: 356,980 |
Open: | $ 44.66 | Volume: | 356,980 | |
---|---|---|---|---|
High: | $ 46.69 | Yield(%) | 0.00 | |
Low: | $ 44.19 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 8.16B | |
EPS ($) | -2.60 | Shares Out: | 182.28M |
% Price Change (last 4 weeks): | 8.22 |
---|---|
% Price Change (last 13 weeks): | -20.72 |
% Price Change (last 26 weeks): | -24.30 |
% Price Change (last 52 weeks): | -35.03 |
% Price Change (year to date): | -25.64 |
Return on Equity (%): | -51.94 |
---|---|
Return on Assets (%): | -32.60 |
Return on Invested Capital (%): | -131.18 |
Gross Profit Margin (%): | 42.25 |
---|---|
Net Profit Margin (%): | -181.75 |
Operating Profit Margin (%): | -155.09 |
|
|
50-day Moving Average: | $43.97 |
---|---|
200-day Moving Average: | $56.94 |
Avg. Daily Vol. (last 50 days): | 1,184,712 |
Avg. Daily Vol. (last 200 days): | 965,732 |
52-wk high: | $77.32 |
52-wk low: | $38.60 |
Bid: | $44.00 |
Ask: | $46.60 |
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
|
Legend Biotech Corporation
2101 Cottontail Lane Somerset NJ 08873 Phone: 1.737.317.5050 Fax: n/a http://www.legendbiotech.com |
Earnings (1year) ($): | -2.60 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 6.88 |
Cash Flow ($): | -2.74 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 37.16 |
Price/Book (x): | 8.75 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 6.83 |
---|---|
Current Ratio (x): | 6.92 |
LT Debt/Equity (x): | 26.01 |
Total Debt/Equity (x): | 26.26 |